The Office of Oncology Drug Products (OODP) at the United States Food and Drug Administration (FDA) has indicated the need for additional clinical study for potential approval of the new drug application (NDA) submitted by Genta Incorporated for their agent Genasense® (oblimersen sodium injection) in the treatment of chronic lymphocytic leukemia.
Genta received the complete response letter from the FDA indicating a necessary amendment to the NDA, as they are not able to approve the application in its present form. Genta will consult with clinical and regulatory advisors about next steps in the process.
Genasense inhibits production of the Bcl-2 protein, which is implicated in cancer cell resistance to chemotherapy through blocking chemotherapy-induced apoptosis.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
